



Hyperbaric Oxygen Therapy (HBOT)

LOB(s): <input checked="" type="checkbox"/> Commercial <input checked="" type="checkbox"/> Medicare	State(s): <input checked="" type="checkbox"/> Idaho <input checked="" type="checkbox"/> Montana <input checked="" type="checkbox"/> Oregon <input checked="" type="checkbox"/> Washington <input type="checkbox"/> Other:
<input checked="" type="checkbox"/> Medicaid	<input checked="" type="checkbox"/> Oregon

Enterprise Policy

PacificSource is committed to assessing and applying current regulatory standards, widely-used treatment guidelines, and evidenced-based clinical literature when developing clinical criteria for coverage determination. Each policy contains a list of sources (references) that serves as the summary of evidence used in the development and adoption of the criteria. The evidence was considered to ensure the criteria provide clinical benefits that promote patient safety and/or access to appropriate care. Each clinical policy is reviewed, updated as needed, and readopted, at least annually, to reflect changes in regulation, new evidence, and advancements in healthcare.

Clinical Guidelines are written when necessary to provide guidance to providers and members in order to outline and clarify coverage criteria in accordance with the terms of the Member's policy. This Clinical Guideline only applies to PacificSource Health Plans, PacificSource Community Health Plans, and PacificSource Community Solutions in Idaho, Montana, Oregon, and Washington. Because of the changing nature of medicine, this list is subject to revision and update without notice. This document is designed for informational purposes only and is not an authorization or contract. Coverage determinations are made on a case-by-case basis and subject to the terms, conditions, limitations, and exclusions of the Member's policy. Member policies differ in benefits and to the extent a conflict exists between the Clinical Guideline and the Member's policy, the Member's policy language shall control. Clinical Guidelines do not constitute medical advice nor guarantee coverage.

Background

Hyperbaric oxygen therapy (HBOT) is the systemic administration of 100% oxygen in a pressurized chamber, typically at a pressure two to three times greater than atmospheric pressure. Treatment is delivered in either a monoplace or multiplace chambers, where patients breath oxygen through a mask or similar device. The therapeutic effect of HBOT results from the combined impact of increased ambient pressure and elevated oxygen concentration, which significantly increases the amount of dissolved oxygen in plasma and enhances oxygen delivery to hypoxic tissues. These physiologic effects support tissue oxygenation in selected conditions.

Criteria

Commercial

Prior authorization is required.

PacificSource considers systemic hyperbaric oxygen therapy (HBOT) medically necessary for **ANY** of the following conditions with initial visit authorization limits as noted per section:

- I. **Up to 5 HBOT sessions for one of the following diagnoses:**
 - A. Carbon monoxide poisoning

B. Cyanide poisoning (including cases occurring in association with carbon monoxide poisoning)

II. Up to 10 HBOT sessions for one of the following diagnoses:

A. Air or gas embolism

B. Decompression sickness

C. Severe blood loss anemia (only when there is overwhelming blood loss and transfusion is impossible because there is no suitable blood available, or religion does not permit transfusions)

D. Crush injury, compartment syndrome or other acute traumatic ischemia

E. Central retinal artery occlusion

III. Up to 20 HBOT sessions for one of the following diagnoses:

A. Clostridial myositis or myonecrosis (gas gangrene)

B. Idiopathic sudden sensorineural hearing loss

C. Necrotizing soft tissue infections

D. Compromised skin grafts and flaps, where hypoxia or decreased perfusion has compromised viability acutely (not for maintenance of split thickness skin grafts or artificial skin substitutes)

E. Thermal burns when **ONE** of the following is met:

1. Greater than 20% Body Surface Area (BSA)

2. full-thickness burns to hands, feet, face, or perineum

E. Intracranial abscess

F. Osteomyelitis (refractory) in patients that meet the following criteria:

1. Chronic osteomyelitis that persists or recurs after 6 weeks of antimicrobial therapy

G. Radiation injury when **ONE** or more of the following is met:

1. Radiation-induced head and neck soft tissue injury

2. Radiation-induced hemorrhagic cystitis

3. Radiation-induced osteonecrosis before and after extraction of tooth in irradiated field

4. Radiation-induced proctitis

H. Diabetic wounds of the lower extremities when **ALL** of the following criteria is met:

1. Wound classified as Wagner grade III or higher

2. Member has failed an adequate course (at least 30 days) of standard wound therapy (e.g., vascular patency of affected extremity, optimization of nutritional status and glucose control, debridement by any means to remove devitalized tissue, maintenance of a clean, moist bed of granulation tissue with appropriate moist dressings, appropriate off-loading, and necessary treatment to resolve any infection that might be present)

Note: The use of HBOT therapy is covered as adjunctive therapy only after there are no measurable signs of healing for at least 30-days of treatment with standard wound therapy and must be used in addition to standard wound care.

IV. HBOT sessions beyond the above guidelines require Medical Director review and must have the following:

- A.** Measurable signs of healing demonstrated within any 30-day period of treatment
- B.** Wounds must be evaluated at least every 30 days during administration of hyperbaric oxygen therapy.

V. HBOT sessions for osteoradionecrosis prophylaxis (pre- and post-treatment for dental surgery) involving a previously irradiated jaw requires Medical Director/Dental Medical Director review and must meet **ALL of the following:**

- A.** Documentation of relationship between extraction site and radiation site (prior to image-guided or intensity-modulated radiation therapy)
- B.** Planned use Pre- and Postoperatively (e.g., MARX protocol)
 - 1.** Five days per week:
 - a.** 20 HBOT sessions preoperatively, followed by 10 sessions immediately postoperatively.

Medicaid

PacificSource Community Solutions follows an internal hierarchal process in the “Clinical Criteria Used in UM Decisions” policy for coverage of Hyperbaric Oxygen Therapy. PCS covers these services when the condition and service(s) pair on a funded line on the HERC Prioritized List of Health Services, Guideline Note 107 criteria is fulfilled, and service(s) are medically necessary and appropriate for the specific member. Additional coverage options for unfunded conditions and services are provided as described in Covered Services OAR 410-141-3820. Topical Oxygen therapy has insufficient evidence of effectiveness per Excluded Services Guideline E2. Treatment of Hyperbaric Oxygen Therapy may be limited or excluded if the service meets the criteria outlined in OARs 410-141-3825 and 410-120-1200, except as otherwise provided in the Covered Services Rule.

PacificSource Community Solutions (PCS) follows the Early and Periodic Screening, Diagnostic, and Treatment (EPSDT) coverage requirements in OAR 410-151-0000 through 410-151-0003 for EPSDT beneficiaries. Relevant coverage guidance, including but not limited to Guideline Note 107 and Excluded Services Guideline E2, may be used to assist in informing a determination of medical necessity and medical appropriateness during the individual case review. A case-by-case review for EPSDT Medical Necessity and EPSDT Medical Appropriateness as defined in OAR 410-151-0001 is required prior to denying. Refer to the Early and Periodic Screening, Diagnostic, and Treatment (EPSDT) policy for details.

Medicare

PacificSource Medicare follows National Coverage Determination 20.29 for Hyperbaric Oxygen Therapy.

Experimental/Investigational/Unproven

PacificSource considers the use of systemic HBOT for all other indications experimental, investigational, or unproven.

PacificSource considers Topical Hyperbaric Oxygen Therapy (TOT) to be experimental, investigational, or unproven.

PacificSource considers “Mild” HBOT delivered in soft sided inflatable chambers to be experimental, investigational, or unproven.*

PacificSource considers Hyperbaric Oxygen Therapy (HBOT) for the treatment of post-COVID conditions to be experimental, investigational, or unproven.*

Note: * indicates the item remains E/I/U but will not be reviewed annually by the NTOC Committee, unless requested.

Note: PacificSource Community Solutions and PacificSource Medicare require items listed on this policy’s E/I/U list, to be reviewed by medical necessity review guidelines. Please see related policy, “*Clinical Criteria Used in UM Decisions*” to review criteria hierarchy and “*Medical Necessity Reviews*” for determination of coverage and medical necessity guidelines.

Coding Information

The following list of codes are for informational purposes only and may not be all-inclusive. Deleted codes and codes which are not effective at the time the service is rendered may not be eligible for reimbursement.

- 99183 Physician or other qualified health care professional attendance and supervision of hyperbaric oxygen therapy, per session-
- A4575 Topical hyperbaric oxygen chamber, disposable
- E0446 Topical oxygen delivery system, not otherwise specified, includes all supplies and accessories
- G0277 Hyperbaric oxygen under pressure, full body chamber, per 30-minute interval

CPT® codes, descriptions and materials are copyrighted by the American Medical Association (AMA).

HCPCS® codes, descriptions and materials are copyrighted by Centers for Medicare and Medicaid Services (CMS).

Definitions

Atmospheric Pressure - Pressure caused by the weight of the atmosphere. At sea level it has a mean value of one atmosphere but reduces with increasing altitude.

Carbon Monoxide - Colorless, odorless, poisonous gas; when inhaled, it combines with blood hemoglobin and prevents oxygen transfer.

Cyanide Poisoning - Occurs when cyanide is ingested or inhaled. Cyanide is a highly toxic chemical that exists in gas or crystal form.

Debridement - The surgical removal of foreign material or dead, damaged, or infected tissue from a wound.

Decompression Illness (DCI) - Any of the diving disorders caused by the presence of bubbles of gas in a diver's body; bubbles may be caused by gas embolism producing breaks in the tissues surrounding body cavities due to high pressure gas.

Gangrene - Death of tissue usually in considerable mass and generally associated with loss of vascular (nutritive) supply and followed by bacterial invasion and putrefaction.

Granulation - Minute red granules of new capillaries formed on the surface of a wound in healing.

Ischemia - Deficient supply of arterial blood to a body part due to obstruction.

Necrotizing Fasciitis - A bacterial infection that attacks the soft tissue and the fascia (sheath of tissue covering the muscle).

Osteomyelitis - An acute or chronic bone infection that can be caused by bacteria or fungi and can lead to destruction of the bone.

Osteoradionecrosis - Necrosis (death) of bone caused by exposure to ionizing radiation.

Oxyhemoglobin - A chemical compound of hemoglobin and oxygen that is present in arterial blood and transports oxygen to the tissues.

Refractory Osteomyelitis - Bone infection which has not responded to appropriate treatment.

Wagner Classification - Staging/Grading of Diabetic Foot Ulcers - A classification system used to assess wound parameters in individuals with diabetes, including the depth of penetration, the presence of osteomyelitis or gangrene, and the extent of tissue necrosis. The wound grades are defined as follows:

- **Grade 0** - No open lesion; skin changes including erythema (reddening), whitening, mild exfoliation (scaling), or luminous variations (shining, glowing, or dullness in relation to surrounding skin)
- **Grade 1** - Superficial ulcer without penetration to deeper layers
- **Grade 2** - Ulcer penetrates to tendon, bone, or joint
- **Grade 3** - Lesion has penetrated deeper than grade 2 and there is abscess, osteomyelitis, pyarthrosis, plantar space abscess, or infection of the tendon and tendon sheaths
- **Grade 4** - Wet or dry gangrene in the toes, forefoot, knee area, buttocks, elbow, or fingers
- **Grade 5** - Gangrene involves the whole foot or such a percentage that no local procedures are possible and amputation (at least at the below the knee level) is indicated.

Related Policies

Clinical Criteria Used in UM Decisions

Clinical Resources Used for Medical Necessity Determinations When No Other UM Clinical Criteria or Guideline Exists

Early and Periodic Screening, Diagnostic, and Treatment (EPSDT)

References

American Academy of Otolaryngology-Head and Neck Surgery®. (August 1, 2019). Sudden Hearing Loss: Update to Guideline to Improve Implementation and Awareness.

<https://www.entnet.org/resource/aao-hnsf-updated-cpg-shl-press-release-fact-sheet/>

Brouwer, R. J., Lalieu, R. C., Hoencamp, R., van Hulst, R. A., & Ubbink, D. T. (2020). A systematic review and meta-analysis of hyperbaric oxygen therapy for diabetic foot ulcers with arterial insufficiency. *Journal of vascular surgery*, 71(2), 682–692.e1. <https://doi.org/10.1016/j.jvs.2019.07.082>

- Buboltz, J. B., Hendriksen, S., & Cooper, J. S. (2022). Hyperbaric Soft Tissue Radionecrosis. In StatPearls. StatPearls Publishing. <https://www.ncbi.nlm.nih.gov/books/NBK482261>
- Buboltz, J. B., Hendriksen, S., & Cooper, J. S. (2024). Osteoradionecrosis. In StatPearls. StatPearls Publishing. <https://www.ncbi.nlm.nih.gov/books/NBK430917/>
- Centers for Medicare & Medicaid Services. (2017). National Coverage Determination (NCD) for Hyperbaric Oxygen Therapy (20.29). <https://www.cms.gov/medicare-coverage-database/view/ncd.aspx?ncdid=12>
- Edwards, M., & Cooper, J. S. (2023). Hyperbaric treatment of thermal burns. In StatPearls. StatPearls Publishing. <https://www.ncbi.nlm.nih.gov/books/NBK23152/>
- Eskes, A. M., Ubbink, D. T., Lubbers, M., Lucas, C., & Vermeulen, H. (2013). Hyperbaric oxygen therapy for treating acute surgical and traumatic wounds. Cochrane Database of Systematic Reviews, (12), CD008059. <https://doi.org/10.1002/14651858.CD008059.pub3>
- Galloway, T., & Amdur, R. (September 12, 2023). Management of late complications of head and neck cancer and its treatment. UpToDate. <https://www.uptodate.com/contents/3365#!> U.S. Food and Drug Administration (FDA). (July 26, 2021). Hyperbaric Oxygen Therapy: Get the Facts. Accessed March 1, 2022. <https://www.fda.gov/consumers/consumer-updates/hyperbaric-oxygen-therapy-get-facts>
- Harch, P. G., Andrews, S. R., Rowe, C. J., Lischka, J. R., Townsend, M. H., Yu, Q., & Mercante, D. E. (2020). Hyperbaric oxygen therapy for mild traumatic brain injury persistent postconcussion syndrome: a randomized controlled trial. *Medical gas research*, 10(1), 8–20. <https://doi.org/10.4103/2045-9912.279978>
- Hedetoft, M., Bennett, M. H., & Hyldegaard, O. (2021). Adjunctive hyperbaric oxygen treatment for necrotising soft-tissue infections: A systematic review and meta-analysis. *Diving and hyperbaric medicine*, 51(1), 34–43. <https://doi.org/10.28920/dhm51.1.34-43>
- MCG Hyperbaric Oxygen: A-0250 (AC).
- Mohandas, R., Mohapatra, S., Narkhede, R., & Kheur, S. (2024). Effectiveness of hyperbaric oxygen therapy in the management of osteoradionecrosis of the jaw: A systematic review. *Journal of Health and Allied Sciences NU*, 14, 295–302. <https://www.thieme-connect.com/products/ejournals/pdf/10.1055/s-0043-1770981.pdf>
- Molina-Vega, J., Pferdehirt, R. E., & Vardanian, A. J. (2026). Hyperbaric oxygen therapy in burn care: A systematic review of current evidence. *Journal of Burn Care & Research*. Advance online publication. <https://doi.org/10.1093/jbcr/irag026>
- Monteiro-Soares, M., Hamilton, E. J., Russell, D. A., Srisawasdi, G., Boyko, E. J., Mills, J. L., Jeffcoate, W., & Game, F. (2023). Guidelines on the classification of foot ulcers in people with diabetes (IWGDF 2023 update). *Diabetes/Metabolism Research and Reviews*, e3669. <https://iwgdfguidelines.org/wp-content/uploads/2023/07/IWGDF-2023-03-Classification-Guideline.pdf>
- Moon, R. E. (2019). Hyperbaric oxygen therapy indications. UHMS Guidelines. <https://www.uhms.org/resources/featured-resources/hbo-indications.html>
- National Institute for Health and Care Excellence. (May 19, 2021). Managing pressure ulcers in neonates, infants, children and young people. Accessed March 1, 2022. <https://pathways.nice.org.uk/pathways/pressure-ulcers/managing-pressure-ulcers-in-neonates-infants->

[children-and-young-people#content=view-index&path=view%3A/pathways/pressure-ulcers/pressure-ulcers-overview.xml](#)

National Library of Medicine. Medical Encyclopedia. Hyperbaric oxygen therapy. Available at: <http://www.nlm.nih.gov/medlineplus/ency/article/002375.htm>

Oregon Health Authority. Oregon Administrative Rules (OARs). Health Systems: Medical Assistance Programs – Chapter 410
<https://secure.sos.state.or.us/oard/displayChapterRules.action?selectedChapter=87>

Oregon Health Plan. The Health Evidence Review Commission (HERC) Prioritized List of Health Services <https://www.oregon.gov/oha/HSD/OHP/Pages/Prioritized-List.aspx>

Serena, T. E., Gelly, H., Bohn, G. A., Niezgoda, J. A., & American College of Hyperbaric Medicine (2014). The American College of Hyperbaric Medicine consensus statement on physician credentialing for hyperbaric oxygen therapy. *Advances in skin & wound care*, 27(8), 349–351. Accessed July 12, 2017, March 29, 2018, April 1, 2019, March 18, 2020, and March 1, 2022.
http://journals.lww.com/aswcjournal/Fulltext/2014/08000/The_American_College_of_Hyperbaric_Medicine.5.aspx

Sharma, R., Sharma, S. K., Mudgal, S. K., Jelly, P., & Thakur, K. (2021). Efficacy of hyperbaric oxygen therapy for diabetic foot ulcer, a systematic review and meta-analysis of controlled clinical trials. *Scientific reports*, 11(1), 2189. <https://doi.org/10.1038/s41598-021-81886-1>

Undersea and Hyperbaric Medical Society. Hyperbaric Oxygen Committee, & Moon, R. E. (2019). *Hyperbaric Oxygen Therapy Indications, 14TH Edition*. Edited by Richard E Moon, (14th ed.). Van Haren Publishing. <https://www.uhms.org/resources/featured-resources/hbo-indications.html>

Zulkowski, K., Ayello, E. A., & Wexler, S. (2003). Validation of Wagner’s classification: A literature review. *Wounds*, 15(2), 39–47. <https://www.hmpgloballearningnetwork.com/site/wmp/content/validation-wagners-classification-a-literature-review>

Appendix

Policy Number:

Effective: 4/1/2020

Next review: 5/1/2027

Policy type: Enterprise

Author(s):

Depts: Health Services

Applicable regulation(s): 42 CFR § 422.101(b)-(c); OARs 410-120-1200, 410-141-3820, 140-141-3825, 410-151-0001, 410-151-0002, 410-151-0003.

OPs Approval: 3/2026